GULP1 as a Downstream Effector of the Estrogen Receptor-β Modulates Cisplatin Sensitivity in Bladder Cancer

被引:0
作者
Tatenuma, Tomoyuki [1 ,2 ]
Matsukawa, Takuo [1 ,2 ]
Goto, Takuro [1 ,2 ]
Jiang, Guiyang [1 ,2 ]
Sharma, Adhya [1 ,2 ]
Najafi, Mohammad amin elahi [1 ,2 ]
Teramoto, Yuki [1 ,2 ]
Miyamoto, Hiroshi [1 ,2 ,3 ,4 ]
机构
[1] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, 601 Elmwood Avenue,Box 626, Rochester, NY 14642 USA
[2] Univ Rochester, James P Wilmot Canc Inst, Med Ctr, Rochester, NY USA
[3] Univ Rochester, Med Ctr, Dept Urol, Rochester, NY USA
[4] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA
关键词
Bladder cancer; chemotherapy; cisplatin; estrogen receptor-beta; GULP1; ANDROGEN RECEPTOR; EXPRESSION;
D O I
10.21873/cgp.20472
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Precise molecular mechanisms underlying resistance to cisplatin-based chemotherapy remain unclear, while the activity of estrogen receptor-/3 (ER/3) has been suggested to be associated with chemosensitivity in urothelial cancer. We aimed to determine if GULP1, an adapter protein known to facilitate phagocytosis, could represent a downstream effector of ER/3 and thereby modulate cisplatin sensitivity in bladder cancer. Materials and Methods: GULP1 expression and cisplatin cytotoxicity were compared in bladder cancer lines. Immunohistochemistry was used to determine the expression of GULP1 and ER/3 in two sets of tissue microarray (TMA) consisting of transurethral resection specimens. Results: The levels of GULP1 expression were considerably higher in ER/3- knockdown sublines than in the respective control ER/3-positive sublines. Estradiol treatment reduced GULP1 expression in ERa-negative/ER/3-positive lines, which was restored by the anti- estrogen tamoxifen. Chromatin immunoprecipitation assay revealed the binding of ER/3 to the GULP1 promoter in bladder cancer cells. Moreover, GULP1 knockdown sublines were significantly more resistant to cisplatin treatment, but not to other chemotherapeutic agents, including gemcitabine, methotrexate, vinblastine, and doxorubicin. In the first set of TMA (n=129), the expression of ER/3 and GULP1 was inversely correlated (p=0.023), and ER/3(-)/GULP1(+) in 51 muscle- invasive tumors was associated with significantly lower risk of disease progression and cancer-specific mortality. Similarly, in the second set (n=43), patients with ER/3(-)/GULP1(+) muscle- invasive disease were significantly (p=0.021) more likely to be responders to cisplatin-based neoadjuvant chemotherapy before radical cystectomy. Conclusion: ER/3 activation was found to reduce the expression of GULP1 as a direct downstream target in bladder cancer cells, resulting in the induction of cisplatin resistance.
引用
收藏
页码:557 / 565
页数:9
相关论文
共 50 条
  • [1] Estrogen receptor-β signaling induces cisplatin resistance in bladder cancer
    Goto, Takuro
    Kashiwagi, Eiji
    Jiang, Guiyang
    Nagata, Yujiro
    Teramoto, Yuki
    Baras, Alexander S.
    Yamashita, Shinichi
    Ito, Akihiro
    Arai, Yoichi
    Miyamoto, Hiroshi
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (08): : 2523 - 2534
  • [2] Androgen Receptor Signaling Induces Cisplatin Resistance via Down-Regulating GULP1 Expression in Bladder Cancer
    Teramoto, Yuki
    Jiang, Guiyang
    Goto, Takuro
    Mizushima, Taichi
    Nagata, Yujiro
    Netto, George J.
    Miyamoto, Hiroshi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (18)
  • [3] Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer
    Jiang, Guiyang
    Teramoto, Yuki
    Goto, Takuro
    Mizushima, Taichi
    Inoue, Satoshi
    Ide, Hiroki
    Nagata, Yujiro
    Kashiwagi, Eiji
    Baras, Alexander S.
    Netto, George J.
    Yang, Zhiming
    Miyamoto, Hiroshi
    CANCERS, 2021, 13 (05) : 1 - 13
  • [4] GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer
    Najafi, Mohammad Amin Elahi
    Yasui, Masato
    Teramoto, Yuki
    Tatenuma, Tomoyuki
    Jiang, Guiyang
    Miyamoto, Hiroshi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
  • [5] Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer
    Kashiwagi, Eiji
    Ide, Hiroki
    Inoue, Satoshi
    Kawahara, Takashi
    Zheng, Yichun
    Reis, Leonardo O.
    Baras, Alexander S.
    Miyamoto, Hiroshi
    ONCOTARGET, 2016, 7 (31) : 49169 - 49179
  • [6] Latrophilin-3 as a downstream effector of the androgen receptor induces bladder cancer progression
    Goto, Takuro
    Teramoto, Yuki
    Nagata, Yujiro
    Miyamoto, Hiroshi
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [7] Androgen receptor signals reduce sensitivity to cisplatin in bladder cancer cells
    Kashiwagi, Eiji
    Kawahara, Takashi
    Ide, Hiroki
    Netto, George
    Baras, Alexander
    Eto, Masatoshi
    Miyamoto, Hiroshi
    CANCER SCIENCE, 2018, 109 : 303 - 303
  • [8] Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-β
    Tang, Hexiao
    Liao, Yongde
    Chen, Guang
    Xu, Liqiang
    Zhang, Chao
    Ju, Sheng
    Zhou, Sheng
    MEDICAL ONCOLOGY, 2012, 29 (04) : 2640 - 2648
  • [9] MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1
    Li, Peng
    Yang, Xiao
    Cheng, Yidong
    Zhang, Xiaolei
    Yang, Chengdi
    Deng, Xiaheng
    Li, Pengchao
    Tao, Jun
    Yang, Haiwei
    Wei, Jifu
    Tang, Jingyuan
    Yuan, Wenbo
    Xu, Xiaoting
    Lu, Qiang
    Gu, Min
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2017, 41 (03) : 921 - 932
  • [10] Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer
    Tokuda, Emi
    Seino, Yuko
    Arakawa, Atsushi
    Saito, Mitsue
    Kasumi, Fujio
    Hayashi, Shin-ichi
    Yamaguchi, Yuri
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (02) : 427 - 436